Why haven’t biosimilars gained ground in the U.S.?
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
Biosimilars
Five things for pharma marketers to know: Wednesday, October 25, 2017
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer’s drug; GSK Q3 sales driven by HIV, respiratory drugs
Five things for pharma marketers to know: Monday, October 23, 2017
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
Five things for pharma marketers to know: Wednesday, September 20, 2017
Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche’s oncology business under siege from biosimilars
Five things for pharma marketers to know: Tuesday, September 19, 2017
Only three of the seven FDA-approved biosimilars are available for sale; Teva to sell off women’s health portfolio; the FDA approves GSK’s COPD combo
Five things for pharma marketers to know: Friday, September 15, 2017
The FDA approves first cancer biosimilar; it also approves Bayer’s new lymphoma drug; clinical-trial participation for gynecological cancer drops
Five things for pharma marketers to know: Monday, August 28, 2017
Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI’s Humira biosimilar
Five things for pharma marketers to know: Friday, August 25, 2017
Google surveys for depression; patients with diabetes that adhere to their regimen had fewer ER visits; Biogen, Samsung scores Humira biosimilar approval in EU
Five things for pharma marketers to know: Tuesday, August 15, 2017
Pfizer accuses J&J of limiting biosimilar uptake; Trump again criticizes high drug prices; WebMD to reposition site to help consumers manage their health
Five things for pharma marketers to know: Monday, June 12, 2017
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus’ Neulasta biosimilar; only 17% of Americans find health industries to be innovative
